AI-assisted molecular screening, human tyrosinase validation, and supramolecular delivery—built for a skin type the brightening category has historically underserved

The Gap the Market Has Been Ignoring

Oily skin presents a specific and underserved challenge in the brightening category. Excess sebum production, pore congestion, blemish-prone skin, and UV-induced sebum oxidation create a complex skin environment that conventional brightening actives were not designed to address—and in some cases actively conflict with.

The result is a meaningful consumer segment that has been forced to choose: brightening or oil control, visible skin tone improvement or a texture that works for their skin type.

Nanohealth's LumiClear was developed specifically to close that gap—combining a precisely validated brightening active with demonstrated benefits for oil control and skin clarity, delivered via a supramolecular carrier system that meaningfully improves dermal residence.

Why the Brightening Category Needed a Better Screening Model

The efficacy limitations of many established brightening actives trace back to a methodological problem at the screening stage: the use of mushroom tyrosinase as the primary assay model.

Tyrosinase is the rate-limiting enzyme in melanin biosynthesis—a copper-dependent oxidoreductase that catalyzes the initial oxidation of tyrosine, setting the pigmentation cascade in motion. Inhibiting tyrosinase activity is the mechanism underpinning most of the brightening category's core actives.

The problem is that mushroom tyrosinase (Agaricus bisporus)—long the default model because it is commercially accessible in active form—has been demonstrated to differ substantially from human tyrosinase in catalytic activity, substrate specificity, active site architecture, and copper-binding region structure. An ingredient that performs well against mushroom tyrosinase does not necessarily perform well against the enzyme as it actually functions in human skin. This discrepancy has contributed to a persistent pattern in the category: strong in-vitro screening results that do not translate into meaningful skin tone outcomes.

Nanohealth's approach was to build the screening model around human tyrosinase from the outset—a model that reflects the enzyme's actual structure and behavior in human melanocytes, and that the cosmetic industry increasingly recognizes as the appropriate benchmark for meaningful brightening ingredient evaluation.

The AI Screening Platform: 2,000+ Candidates, One Validated Active

Using its proprietary MolFunnel AI-assisted molecular screening platform, Nanohealth evaluated more than 2,000 brightening candidates against a human tyrosinase model. The process integrates molecular docking simulation, structural fit analysis, and progressive filtering—functioning as a computational funnel that identifies the candidates with the strongest theoretical affinity for the human enzyme's active site before any wet chemistry is performed.

The compound that emerged as the lead candidate was p-hydroxycinnamic acid—a naturally occurring phenylpropanoid.

Notably, p-hydroxycinnamic acid does not score particularly well on mushroom tyrosinase assays. This is precisely the point: under conventional screening protocols, it would likely have been filtered out at an early stage. Against human tyrosinase, however, its molecular docking profile is comparable to thiamidol (isobutylamido thiazolyl resorcinol)—one of the most clinically validated brightening actives currently in the market. The published literature confirms inhibitory potency against human tyrosinase approximately 100-fold greater than kojic acid under equivalent conditions.

The Delivery Problem—and How Supramolecular Encapsulation Solves It

Identifying a high-performing active is only part of the formulation challenge. P-hydroxycinnamic acid has a documented limitation in published literature: poor dermal penetration. Biological membranes are lipophilic structures, and passive diffusion through them requires a molecule that can bridge water solubility (for distribution in the aqueous phase) and lipophilicity (for membrane penetration). P-hydroxycinnamic acid's penetration profile has historically constrained its practical application in topical formulations.

Nanohealth's supramolecular encapsulation technology addresses this directly. The carrier system improves the aqueous-phase compatibility of the active without modifying its molecular structure—preserving the lipophilicity that enables membrane penetration while making it processable in standard aqueous formulation environments.

The measurable outcome: skin residence of encapsulated p-hydroxycinnamic acid in LumiClear™is 29.7 times greater than unencapsulated p-hydroxycinnamic acid under equivalent conditions. The active reaches the site of action at concentrations sufficient to produce a meaningful biological effect—resolving the gap between strong in-vitro data and limited on-skin performance that has characterized much of the category.

A Four-Dimension Efficacy Profile Built for Oily Skin

LumiClear's development was explicitly scoped around the specific needs of oily and combination skin—not as a secondary consideration, but as the primary design brief. The result is an active with a multi-dimensional profile that addresses the interconnected concerns of this skin type.

Skin tone appearance

Efficacy assessment uses a multi-parameter approach: melanin index measurement, individual typology angle (ITA°) values, and visible evaluation of skin tone uniformity and pore appearance—reflecting the way skin tone improvement is actually perceived rather than measured against a single enzyme assay output.

Protection against the appearance of UV-related skin changes

Both in-vitro and in-vivo data indicate that p-hydroxycinnamic acid, the active compound in LumiClear, demonstrates activity relevant to the visible appearance of UV-related skin tone changes. For oily skin specifically, UV exposure drives sebum oxidation—a distinct pathway from UV-induced melanogenesis that contributes to a dull, uneven complexion appearance. Addressing this pathway is part of LumiClear's differentiated positioning.

Regulatory note: LumiClear is a cosmetic ingredient. It does not provide UV protection in the regulatory sense—no SPF claim should be associated with its use. "Protection against UV-related skin changes" in a cosmetic context refers to the appearance of skin tone, not to UV filtering.

Oil control

Consumer-perceivable sebum reduction within a standard product use cycle—directly addressing the texture and appearance concerns that have historically made the brightening category a poor fit for oily skin types.

Blemish appearance

Sebum overproduction and inflammatory response are the two primary drivers of blemish-prone skin. LumiClear™'s formulation profile addresses both pathways, recognizing that visible skin clarity is as meaningful to oily skin consumers as skin tone evenness—and that the two goals are biologically connected.

Market Context

China's skin brightening market is projected to reach approximately RMB 674 billion by 2026 (Jinggu Agricultural Think Tank), with close to 70% of consumers reporting a clear skin tone improvement priority—a figure that rises meaningfully in the spring and summer seasons. Within this market, oily skin types represent approximately 25% of consumers. Survey data indicates that 72% of consumers express strong interest in brightening products formulated specifically for their skin type—a figure that points directly to the gap that LumiClear™was developed to fill.

Formulation Guidance

LumiClear is suitable for incorporation into brightening serums, lightweight emulsions, gel-creams, and fluid textures designed for oily or combination skin. Its supramolecular carrier format improves processability in aqueous formulation environments.

For specific technical data, suggested use levels, compatibility information, and safety documentation, please contact the Nanohealth technical team.

Conclusion

LumiClear makes the case that skin type should be a primary variable in brightening ingredient selection—not an afterthought managed at the formulation stage with texture modifiers and oil-control additives.

By starting with a human tyrosinase screening model, the active compound at its core was identified on the basis of how it actually behaves in human skin biology. By addressing the penetration limitation through supramolecular encapsulation, the gap between laboratory performance and on-skin outcome is closed. And by building the efficacy profile around the specific needs of oily and combination skin—skin tone, sebum management, and blemish appearance—LumiClear gives formulators a single active that speaks to a consumer segment the category has long served inadequately.

For oily skin, the choice between brightening and everything else it needs does not have to be a compromise.